ClinicalTrials.gg
RecruitingNCT07279558CAPUpdated Sep 16, 2026

Cannabidiol and Alcohol Use Disorder Phenotypes

A Phase 2 interventional study of Full-Spectrum Cannabidiol (CBD) and Broad-Spectrum Cannabidiol (CBD) in Alcohol Use Disorder, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by University of Colorado, Denver · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing cannabidiol in Alcoholism — 4 open to participants now, 4 under way, 2 of them phase 3. Cannabidiol · Alcoholism.

Planned enrollment
2nd of 12
150 · median 49
Started
2026
with 1 other
Phase 2
5 of 12
2 open now
Registered
12th of 12
by date
Lead sponsor
3 of 12
University of Colorado, Denver

Among the 12 studies testing cannabidiol in Alcoholism, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2026, is one of 5 in phase 2, and was the 12th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

4 of the 12 studies testing cannabidiol in Alcoholism are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing cannabidiol in Alcoholism, or all of them as a file.
02

Study summary

The goal of this study is to learn how CBD affects drinking in people who drink alcohol regularly. Researchers want to see if CBD can help people drink less and reduce problems related to alcohol use.

Read the detailed description

Your participation will include up to five in-person visits over about 13 weeks, including a screening visit, a visit to get your medication, a midpoint visit, an experimental lab session, and a final follow-up visit. You will be assigned to a study medication which you will take daily for 8 weeks while completing daily surveys and weekly virtual check-ins with the research team. During the experimental lab session visit, you will be offered alcohol to drink at the bar lab.

03

Conditions studied

  • Alcohol Use Disorder

Browse trials for

Keywords

  • Alcohol
  • Cannabidiol
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 21-65
  2. Have used CBD and cannabis at least once in the last year
  3. Regularly drink alcohol
  4. Able to provide and attend in-person study visits

Exclusion criteria

Exclusion Criteria:

  1. Current use of medications known to have major interaction with Epidiolex, Marinol, or alcohol
  2. Current use of antiepileptic medication or any psychotropic medication besides antidepressants
  3. Pregnant, nursing, or planning a pregnancy
  4. Medical conditions that contraindicates the use of CBD or alcohol
  5. Current medical conditions that may require intensive care during the study period

Not everyone will qualify to be in the study. Other inclusion and exclusion criteria will be evaluated by the study team.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Full-Spectrum CBD

    Subjects will take 200 mg of full-spectrum CBD (\[fsCBD\] CBD that contains \<0.3% THC) daily for 8 weeks. The total dose is split into a morning and evening dose, such that participants in the fsCBD condition will take approximately 100mg fsCBD in the morning (2 capsules) and 100mg fsCBD in the evening (2 capsules).

    Drug: Full-Spectrum Cannabidiol (CBD)

  • Experimental
    Broad- Spectrum CBD

    Subjects will take 200 mg of broad-spectrum CBD (\[bsCBD\] CBD that contains no THC) daily for 8 weeks. The total dose is split into a morning and evening dose, such that participants in the bsCBD condition will take approximately 100mg bsCBD in the morning (2 capsules) and 100mg bsCBD in the evening (2 capsules).

    Drug: Broad-Spectrum Cannabidiol (CBD)

  • Placebo comparator
    Placebo

    Subjects will take a matching placebo solution (100% Hemp Seed Oil) daily for 8 weeks. The total dose is split into a morning and evening dose, such that participants in the condition will take approximately 100mg hemp seed oil in the morning (2 capsules) and 100mg hemp seed oil in the evening (2 capsules).

    Drug: Placebo

Interventions

  • Dose: Approximately 200mg of full-spectrum CBD (\<0.3% THC) Active Ingredients: Full spectrum hemp extract Other Ingredients: Hemp seed oil, glycerin, gelatine.

    Also known as: Hemp-derived, full-spectrum cannabidiol, Ecofibre USA/Ananda Hemp

  • Dose: Approximately 200mg of broad-spectrum CBD, (0% THC) Active Ingredients: Broad spectrum hemp extract Other Ingredients: Hemp seed oil, glycerin, gelatine.

    Also known as: Hemp-derived, broad-spectrum cannabidiol, Ecofibre USA/Ananda Hemp

  • DrugPlacebo

    Active Ingredients: N/A Other Ingredients: Hemp seed oil, glycerin, gelatine.

    Also known as: 100% Hemp Seed Oil, Ecofibre USA/Ananda Hemp

06

What researchers measure

Primary outcomes

  1. Alcohol Self-Administration During the Bar Lab Task

    Number of drinks (between 0-8) subjects choose to self-administer during the Bar Lab Alcohol Self-Administration Task at the week 8 study visit.

    Time frame: Week 8

  2. Change in Self-Report of Drinking Behavior (Drinks Per Drinking Day)

    Drinks Per Drinking Day (DPDD) during the 12-week study period as reported on Timeline Follow Back at Baseline (prior to treatment), Week 4, Week 8, and Week 12.

    Time frame: Baseline, Week 4, Week 8, and Week 12

  3. Change in Phosphatidylethanol (PEth)

    Phosphatidylethanol (PEth) concentration in blood samples collected at Baseline (prior to treatment), Week 4, Week 8, and Week 12.

    Time frame: Baseline, Week 4, Week 8, and Week 12

Secondary outcomes

  1. Change in Negative Emotionality ANA Domain Score

    This summary score will be calculated for change from baseline to follow-up for each of the four ANA Negative Emotionality Measures (Beck Depression Inventory-II, Beck Anxiety Inventory, State-Trait Anxiety Inventory and Drinker Inventory of Consequences-2R) . We will first subtract baseline raw scores from follow-up raw scores for each measure. The summary score will be comprised of the average of the standardized Z scores of the change scores created for each of the four measures. Z scores will range from -3 to 3 after adjusting for outliers, with higher average Z scores indicating a worse outcome.

    Time frame: Baseline, Week 8

Other outcomes

  1. Change in Gut Microbial Diversity

    Gut microbial diversity from fecal samples collected at Baseline (prior to treatment) and Week 8.

    Time frame: Baseline, Week 8

  2. Change in Gut Permeability (Lipopolysaccharide Binding Protein [LBP])

    Lipopolysaccharide Binding Protein levels in blood samples collected at Baseline (prior to treatment) and Week 8.

    Time frame: Baseline, 8 Weeks

  3. Change in Gut Permeability (CD14)

    CD14 levels in blood samples collected at Baseline (prior to treatment) and Week 8.

    Time frame: Baseline, 8 Weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Investigators will submit all de-identified individual level phenotypic human subjects data from this project to the National Institute on Alcohol Abuse and Alcoholism (NIAAA) Data Archive, which is part of the National Institutes of Mental Health (NIMH) Data Archive (NDA). The project also involves collection of human specimens (fecal samples) which will generate non-human genomic data. Specifically, investigators plan to generate 300 (150 subjects x 2 timepoints) human gut microbiota metagenomes (i.e., gut microbiome). Deidentified genomic data (microbiome sequencing from the fecal samples) will be uploaded to the appropriate data repository upon NIH program administrator determination (NDA or the database of Genotypes and Phenotypes [dbGaP]). Participants will be given the option in the consent/HIPAA form to allow the use of any leftover samples to bank for future undetermined analyses not specified in the protocol.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Human phenotypic data will be uploaded at least twice a year, following NIMH Data Archive (NDA) requirements. Non-human genomes from fecal samples will be shared within 12 months of processing and genotyping all meta-genomes.

Access criteria: Data access will be through the National Institute of Mental Health Data Archive (NDA) and/or the database of Genotypes and Phenotypes (dbGaP).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2029, 40 months after the start.

Of 122 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 40 months is above that.

Counting every sponsor, half of 134 studies reached it within 33 months; a quarter within 21 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Dec 12, 2025
StartActual
Apr 21, 2026
Primary completionEst.
Aug 31, 2029
CompletionEst.
Aug 31, 2029
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07279558
Responsible party
Sponsor
First posted
Dec 12, 2025
Start date
Apr 21, 2026
Primary completion
Aug 31, 2029 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Sep 16, 2026

Study contacts

Hollis C Karoly, PhD
Contact
hollis.karoly@cuanschutz.edu
303-724-7179
Landon Tomb, M.S.
Contact
landon.tomb@cuanschutz.edu
225-244-3429
Hollis C Karoly, PhD
principal investigator · University of Colorado School of Medicine- Anschutz Medical Campus

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion